ES2556454T3 - Proceso para producción de proteínas - Google Patents
Proceso para producción de proteínas Download PDFInfo
- Publication number
- ES2556454T3 ES2556454T3 ES11764561.4T ES11764561T ES2556454T3 ES 2556454 T3 ES2556454 T3 ES 2556454T3 ES 11764561 T ES11764561 T ES 11764561T ES 2556454 T3 ES2556454 T3 ES 2556454T3
- Authority
- ES
- Spain
- Prior art keywords
- filter module
- cell culture
- hemostasis
- culture
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 68
- 230000008569 process Effects 0.000 title claims abstract description 65
- 230000014616 translation Effects 0.000 title description 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 230000023597 hemostasis Effects 0.000 claims abstract description 29
- 102100022641 Coagulation factor IX Human genes 0.000 claims abstract description 25
- 108010076282 Factor IX Proteins 0.000 claims abstract description 25
- 238000004113 cell culture Methods 0.000 claims abstract description 22
- 229960004222 factor ix Drugs 0.000 claims abstract description 21
- 239000000725 suspension Substances 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 230000010412 perfusion Effects 0.000 claims abstract description 13
- 238000000855 fermentation Methods 0.000 claims abstract description 7
- 230000004151 fermentation Effects 0.000 claims abstract description 7
- 238000003306 harvesting Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 description 50
- 235000018102 proteins Nutrition 0.000 description 32
- 238000000605 extraction Methods 0.000 description 14
- 102100023804 Coagulation factor VII Human genes 0.000 description 10
- 108010023321 Factor VII Proteins 0.000 description 10
- 229940012413 factor vii Drugs 0.000 description 10
- 239000002609 medium Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 7
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 238000010924 continuous production Methods 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 102100026735 Coagulation factor VIII Human genes 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 4
- 238000011143 downstream manufacturing Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 239000004695 Polyether sulfone Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229920006393 polyether sulfone Polymers 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10186545 | 2010-10-05 | ||
| EP10186545 | 2010-10-05 | ||
| US39271310P | 2010-10-13 | 2010-10-13 | |
| US392713P | 2010-10-13 | ||
| PCT/EP2011/067372 WO2012045769A1 (en) | 2010-10-05 | 2011-10-05 | Process for protein production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2556454T3 true ES2556454T3 (es) | 2016-01-18 |
Family
ID=43735957
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11764561.4T Active ES2556454T3 (es) | 2010-10-05 | 2011-10-05 | Proceso para producción de proteínas |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10138290B2 (enExample) |
| EP (2) | EP2625262B1 (enExample) |
| JP (2) | JP6282467B2 (enExample) |
| CN (2) | CN107190034A (enExample) |
| ES (1) | ES2556454T3 (enExample) |
| PL (1) | PL2625262T3 (enExample) |
| WO (1) | WO2012045769A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014031690A1 (en) * | 2012-08-20 | 2014-02-27 | Terumo Bct, Inc. | Concentrating components of fluid circulated through a cell growth chamber |
| EP3052613A1 (en) * | 2013-09-30 | 2016-08-10 | Crucell Holland B.V. | Method for the clarification of high density crude cell culture harvest |
| JP6530171B2 (ja) * | 2014-09-09 | 2019-06-12 | 旭化成メディカル株式会社 | 培養産生物の回収方法 |
| AU2017301691B2 (en) * | 2016-07-25 | 2022-07-21 | Repligen Corporation | Alternating tangential flow rapid harvesting |
| EP3700505A4 (en) * | 2017-10-26 | 2021-01-06 | Repligen Corporation | MICRO-ALTERNATIVE TANGENTIAL FLOW INFUSION FILTER, PROCESSING CONTAINER, AND METHODS OF USE THEREOF |
| TWI846694B (zh) * | 2018-05-04 | 2024-07-01 | 美商健臻公司 | 具有過濾系統的灌注式生物反應器 |
| CN108504562A (zh) * | 2018-06-21 | 2018-09-07 | 江苏澳创生物科技有限公司 | 一种发酵生产l-苏氨酸的系统及其应用 |
| CN114127260A (zh) * | 2019-07-16 | 2022-03-01 | 信达生物制药(苏州)有限公司 | 高密度连续接种的细胞培养方法及其应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5864086A (en) | 1985-04-22 | 1986-11-18 | Genetics Institute Inc. | High yield production of active factor ix |
| FI873796A7 (fi) | 1986-01-03 | 1987-09-01 | Genetics Inst | Parannettu menetelmä VIII:c-tekijän tyyppisen proteiinin tuottamiseks i. |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US4956080A (en) * | 1987-08-03 | 1990-09-11 | Microlift Systems, Incorporated | High pressure oxygen-saturated water treatment apparatus |
| JPH066054B2 (ja) | 1987-10-15 | 1994-01-26 | 帝人株式会社 | 動物細胞の培養方法 |
| JPH084495B2 (ja) | 1988-08-19 | 1996-01-24 | 帝人株式会社 | 接着性動物細胞の培養方法 |
| WO1990002175A1 (en) | 1988-08-16 | 1990-03-08 | Novo Nordisk A/S | A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors |
| US6268487B1 (en) * | 1996-05-13 | 2001-07-31 | Genzyme Transgenics Corporation | Purification of biologically active peptides from milk |
| US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
| AT409379B (de) * | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| US6544424B1 (en) | 1999-12-03 | 2003-04-08 | Refined Technology Company | Fluid filtration system |
| ATE449861T1 (de) | 2000-10-20 | 2009-12-15 | Bioneer As | Verfahren zur fermentativen herstellung von heterologen genprodukten in milchsäurebakterien |
| JP2005512524A (ja) * | 2001-11-02 | 2005-05-12 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | ヒト凝固第ｖｉｉ因子ポリペプチド |
| US6960657B2 (en) | 2001-11-02 | 2005-11-01 | Novo Nordisk Healthcare A/G | Human coagulation factor VII polypeptides |
| BR0311978A (pt) | 2002-06-21 | 2005-03-22 | Novo Nordisk Healthcare Ag | Preparação, método para preparar a mesma, formulação farmacêutica, métodos para tratar de uma sìndrome responsiva ao fator vii, para prevenir hemorragias indesejáveis, para prevenir coagulação sanguìnea indesejável e para prevenir as reações mediadas pelo fator tecidual, e, uso de uma preparação |
| US7351688B2 (en) | 2003-02-05 | 2008-04-01 | The Research Foundation Of State University Of New York | Compositions and methods for less immunogenic protein formulations |
| ATE371014T1 (de) | 2003-05-01 | 2007-09-15 | Dsm Ip Assets Bv | Verfahren zur herstellung von biologischen substanzen durch perfusionskultivierung von suspendierten tierischen zellen |
| DK1623023T3 (da) | 2003-05-09 | 2009-03-02 | Crucell Holland Bv | Kulturer af E1-immortaliserede celler og fremgangsmåder til dyrkning deraf til forögelse af produktudbytter derfra |
| EP1673452B1 (en) * | 2003-10-10 | 2015-12-23 | Novo Nordisk Health Care AG | Method for large-scale production of a polypeptide in eukaryote cells |
| KR101050585B1 (ko) * | 2004-03-05 | 2011-07-19 | 디에스엠 아이피 어셋츠 비.브이. | 연속식 살포 및 교호 접선 흐름에 의한 세포 배양 방법 |
| WO2006018204A1 (en) | 2004-08-17 | 2006-02-23 | Zlb Behring Gmbh | Modified vitamin k dependent polypeptides |
| EP1707634A1 (en) | 2005-03-29 | 2006-10-04 | Octapharma AG | Method for isolation of recombinantly produced proteins |
| CN101473029A (zh) | 2006-04-21 | 2009-07-01 | 拜尔健康护理有限责任公司 | 抗凋亡基因在用于灌注培养的哺乳动物细胞中的应用 |
| CN101490239A (zh) * | 2006-07-14 | 2009-07-22 | 帝斯曼知识产权资产管理有限公司 | 改进的细胞培养方法 |
| PT2634243T (pt) | 2006-07-14 | 2017-12-18 | Patheon Holdings I B V | Método para melhorar a cultura de células |
| EP1988101A1 (en) | 2007-05-04 | 2008-11-05 | Novo Nordisk A/S | Improvement of factor VIII polypeptide titers in cell cultures |
| EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
| JP2009045019A (ja) | 2007-08-21 | 2009-03-05 | Toray Ind Inc | タンパク質の製造方法 |
| EP2444491B1 (en) | 2008-04-21 | 2016-11-16 | Novo Nordisk Healthcare Ag | Hyperglycosylated human coagulation factor IX |
| WO2010003759A2 (en) | 2008-06-17 | 2010-01-14 | Dsm Ip Assets B.V. | Cell culturing method |
-
2011
- 2011-10-05 EP EP11764561.4A patent/EP2625262B1/en not_active Revoked
- 2011-10-05 ES ES11764561.4T patent/ES2556454T3/es active Active
- 2011-10-05 US US13/823,847 patent/US10138290B2/en active Active
- 2011-10-05 WO PCT/EP2011/067372 patent/WO2012045769A1/en not_active Ceased
- 2011-10-05 JP JP2013532180A patent/JP6282467B2/ja active Active
- 2011-10-05 CN CN201710499437.8A patent/CN107190034A/zh active Pending
- 2011-10-05 EP EP15174742.5A patent/EP2957628A1/en not_active Withdrawn
- 2011-10-05 CN CN2011800482244A patent/CN103154233A/zh active Pending
- 2011-10-05 PL PL11764561T patent/PL2625262T3/pl unknown
-
2016
- 2016-08-04 JP JP2016153606A patent/JP2016187360A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2625262B1 (en) | 2015-09-23 |
| JP6282467B2 (ja) | 2018-02-21 |
| EP2957628A1 (en) | 2015-12-23 |
| CN107190034A (zh) | 2017-09-22 |
| PL2625262T3 (pl) | 2016-05-31 |
| CN103154233A (zh) | 2013-06-12 |
| US20130244283A1 (en) | 2013-09-19 |
| US10138290B2 (en) | 2018-11-27 |
| JP2016187360A (ja) | 2016-11-04 |
| JP2013538588A (ja) | 2013-10-17 |
| EP2625262A1 (en) | 2013-08-14 |
| WO2012045769A1 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2556454T3 (es) | Proceso para producción de proteínas | |
| ES2743903T3 (es) | Métodos para cambiar el perfil isoeléctrico de un producto proteico y sus usos | |
| ES2657055T3 (es) | Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores | |
| ES2705206T3 (es) | Método de producción de un polipéptido o virus de interés en un cultivo celular continuo | |
| ES2719876T3 (es) | Métodos para replicar un cultivo celular de producción de eculizumab a gran escala | |
| BR112016028891B1 (pt) | Processo de ampliação de escala de cultura de células e método de produção de uma proteína recombinante | |
| ES2547881T5 (es) | Método de producción de factor VII libre de suero y libre de insulina | |
| US20140273206A1 (en) | High density cell banking methods | |
| WO2014059035A1 (en) | Methods and systems for optimizing perfusion cell culture system | |
| US20250084386A1 (en) | Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells | |
| CN101352570B (zh) | 二倍体细胞狂犬疫苗及纯化狂犬疫苗的制备方法 | |
| Oguchi et al. | Food production and gas exchange system using blue-green alga (Spirulina) for CELSS | |
| SE528214C2 (sv) | Förfarande för framställning av blodplättslysat | |
| CN107523555A (zh) | 获得病毒的方法 | |
| WO2023054556A1 (ja) | 細胞培養方法、及び有用物質の製造方法 | |
| KR20140036144A (ko) | 고수율 현탁세포주, 시스템 및 그 제조방법 | |
| CN102776260A (zh) | 一种高效表达重组人凝血八因子的方法 | |
| TW201522634A (zh) | 用於增進重組蛋白質製造之調配物及方法 | |
| CN108368162A (zh) | 一种重组人粒细胞刺激因子的复性及纯化方法 | |
| JPH01101882A (ja) | 動物細胞の培養方法 | |
| CN102406933A (zh) | 一种麻疹减毒活疫苗的制备方法 | |
| CN105838664A (zh) | 一种细胞悬浮培养生产重组人血小板生成素的方法 | |
| Zhang et al. | Factors influencing yields of mesenchymal stem cells derived from human umbilical cord blood | |
| Wagey et al. | THE VALIDATION OF AN ANIMAL COMPONENT-FREE SUSPENSION CULTURE FOR HUMAN MESENCHYMAL STROMAL CELLS IN HORIZONTAL AND VERTICAL WHEEL CULTURE SYSTEM | |
| AU2010332766A1 (en) | Method for optimizing a biopharmaceutical production process |